- Home
- MRC vs CVAC Comparison
MRC vs CVAC Comparison
Compare MRC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRC
- CVAC
- Stock Information
- Founded
- MRC 1921
- CVAC 2000
- Country
- MRC United States
- CVAC Germany
- Employees
- MRC N/A
- CVAC N/A
- Industry
- MRC Industrial Machinery/Components
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- MRC Industrials
- CVAC Health Care
- Exchange
- MRC Nasdaq
- CVAC Nasdaq
- Market Cap
- MRC 1.0B
- CVAC 818.8M
- IPO Year
- MRC 2012
- CVAC 2020
- Fundamental
- Price
- MRC $12.26
- CVAC $3.47
- Analyst Decision
- MRC Strong Buy
- CVAC Strong Buy
- Analyst Count
- MRC 3
- CVAC 2
- Target Price
- MRC $15.00
- CVAC $14.00
- AVG Volume (30 Days)
- MRC 692.3K
- CVAC 535.9K
- Earning Date
- MRC 05-06-2025
- CVAC 05-22-2025
- Dividend Yield
- MRC N/A
- CVAC N/A
- EPS Growth
- MRC N/A
- CVAC N/A
- EPS
- MRC N/A
- CVAC 0.75
- Revenue
- MRC $2,946,000,000.00
- CVAC $554,073,921.00
- Revenue This Year
- MRC $5.78
- CVAC N/A
- Revenue Next Year
- MRC $7.19
- CVAC $38.07
- P/E Ratio
- MRC N/A
- CVAC $4.65
- Revenue Growth
- MRC N/A
- CVAC 895.54
- 52 Week Low
- MRC $9.23
- CVAC $2.22
- 52 Week High
- MRC $15.41
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- MRC 59.91
- CVAC 56.52
- Support Level
- MRC $10.76
- CVAC $3.26
- Resistance Level
- MRC $12.32
- CVAC $3.63
- Average True Range (ATR)
- MRC 0.46
- CVAC 0.21
- MACD
- MRC 0.13
- CVAC 0.01
- Stochastic Oscillator
- MRC 88.14
- CVAC 51.83
About MRC MRC Global Inc.
MRC Global Inc distributes pipes, valves, fittings, and other infrastructure products and services to diversified gas utility, energy, and industrial end-markets. It provides supply chain solutions, technical product service and a digital platform for customers globally. It offers a range of PVF, oilfield supply, valve automation and modification, measurement, instrumentation, and other general and specialty products. Its geographical segments include the United States and International. It generates the majority of its revenue from the United States.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.